| CASE REPORT |
|
| Year : 2013 | Volume
: 3
| Issue : 4 | Page : 163-167 |
|
|
Intravitreal dexamethasone implant for a vitrectomized eye with diabetic macular edema
Tsu-Hua Chen1, Jia-Kang Wang2, Shu-Wen Chang1
1 Department of Ophthalmology, Far Eastern Memorial Hospital, Taipei, Taiwan
2 Department of Ophthalmology, Far Eastern Memorial Hospital; Department of Healthcare Administration and Department of Nursing, Oriental Institute of Technology; Department of Medicine, National Yang Ming University, Taipei, Taiwan
Correspondence Address:
Jia-Kang Wang
Department of Ophthalmology, Far Eastern Memorial Hospital, 21, Section 2, Nan-Ya South Road, Pan-Chiao District, New Taipei City 220
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.1016/j.tjo.2013.04.005
|
|
|
A 71-year-old man suffered from diabetic vitreous hemorrhage in his left pseudophakic eye. He received 20-gauge pars plana vitrectomy and removal of taut posterior hyaloid traction in June 2011. Spectral-domain optical coherence tomography demonstrated cystoid macular edema 1 month after the operation. The macular edema did not respond to macular grid laser. Intravitreal bevacizumab (1.25 mg) was injected, which was effective for managing diabetic macular edema initially. The edema recurred 3 months following the bevacizumab injection. Subsequent intravitreal triamcinolone 1 mg also failed to treat the macular edema. Ozurdex, a dexamethasone implant, was injected intravitreally in January 2012. The central foveal thickness decreased, and visual acuity improved. The effect persisted for 6 months. There was no systemic or ocular adverse event during the follow-up period. This intravitreal dexa-methasone implant could be helpful for diabetic macular edema in vitrectomized eyes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
